Brief: Mei Pharma Reports Clinical Data On Oral Cdk9 Inhibitor Voruciclib At Ash2023
11/12/2023 17:04
Dec 11 (Reuters) - MEI Pharma Inc MEIP.O :
* MEI PHARMA REPORTS CLINICAL DATA ON ORAL CDK9 INHIBITOR
VORUCICLIB AT ASH2023
* MEI PHARMA INC - INITIAL RESULTS FROM CORRELATIVE STUDIES
DEMONSTRATE ON-TARGET REDUCTIONS IN MCL-1 AND RNA POL II P-S2
* MEI PHARMA INC - SAFETY PROFILE OBSERVED TO DATE AS
MONOTHERAPY
AND IN COMBINATION WITH VENETOCLAX SUGGESTS NO OVERLAPPING
TOXICITY
Source text for Eikon: ID:nBw7McCX7a
Further company coverage: MEIP.O
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations